Thrombophilia bloodwork
PreclinicalBiologic
Thrombophilia bloodwork is one of 22 biologic programs targeting Antiphospholipid Syndrome. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
29 competitors in Antiphospholipid Syndrome
#DrugCompanyPhaseTrials
1Eliquis
Bristol-Myers SquibbApproved
Coumadin
AAbbott
Approved
Plaquenil
Alnylam PharmaceuticalsPhase 3
Antiplatelet Drug
FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Approved
Benlysta
GGlaxo Dba Glaxosmithkline
Phase 3
Lovenox
SanofiPhase 2
Lescol
NovartisPhase 2
Rituxan
RochePhase 2
Darzalex
Johnson & JohnsonPhase 2
Rapamune
PPrism Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Antiphospholipid Syndrome1 trial
Comparative Prevalence of Psychiatric Manifestations in Purely Obstetrical Antiphospholipid Syndrome
Terminated·—·N/A·NCT01649479·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Thrombophilia bloodwork. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details